Exploring a new treatment for kidney disease using a specific medication
Advancing ADPKD Treatment with GLP-1RA: A Study of Glucagon-Like Peptide-1 Receptor Agonists' Efficacy, Safety, and Mechanism
This study is looking at whether a type of medication called GLP-1 receptor agonists can help slow down kidney problems in people with autosomal dominant polycystic kidney disease (ADPKD), especially for those who find it hard to stick to other treatments because of side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11167850 on NIH RePORTER |
What this research studies
This research investigates the effectiveness and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as a potential treatment for autosomal dominant polycystic kidney disease (ADPKD). The study aims to understand how these medications can slow the progression of kidney disease, particularly in patients who may struggle with existing treatments due to side effects. By focusing on the relationship between body weight, insulin resistance, and kidney health, the research seeks to provide a pharmacological alternative to lifestyle changes that can be difficult to maintain. Patients will be monitored for changes in kidney volume and overall health throughout the trial.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have been diagnosed with autosomal dominant polycystic kidney disease.
Not a fit: Patients with advanced kidney disease or those who do not have a diagnosis of ADPKD may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a new, effective treatment option for patients with ADPKD, potentially slowing disease progression and improving quality of life.
How similar studies have performed: Previous studies have shown promising results with similar pharmacological approaches in managing kidney disease, indicating potential for success in this research.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Nowak, Kristen Lynn — University of Colorado Denver
- Study coordinator: Nowak, Kristen Lynn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.